DDInter1242 DDInter1435
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticosteroids or other agents in asthma step therapy. Regardless, in 2008-2009, there were FDA-led investigations into the possibility of montelukast to elicit neuropsychiatric effects like agitation, hallucinations, suicidal behaviour, and others in individuals who used the medication. And although these kinds of effects are currently included in the official prescribing information for montelukast,[L6301,L6304,L6307,L6310,L6325,L632
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Montelukast {u} (Compound) treats {v} (Disease) chronic obstructive pulmonary disease
Montelukast {u} (Compound) binds {v} (Gene) CYP2C8
Montelukast {u} (Compound) upregulates {v} (Gene) SESN1
Montelukast {u} (Compound) is included by {v} (Pharmacologic Class) Leukotriene Receptor Antagonists
Montelukast {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Montelukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Montelukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminoglutethimide
Montelukast (Compound) treats chronic obstructive pulmonary disease (Disease)
Montelukast (Compound) binds CYP2C8 (Gene)
Montelukast (Compound) upregulates SESN1 (Gene)
Montelukast (Compound) is included by Leukotriene Receptor Antagonists (Pharmacologic Class)
Montelukast (Compound) causes Aspartate aminotransferase increased (Side Effect)
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide